Navigation Links
Applying Clinical Findings to the Practice of Medicine
Date:2/25/2009

ed the establishment of the Kappa Delta Research Fellowship in Orthopaedics, the first award ever created to honor achievements in the field of orthopaedic research. The first annual award, a single stipend of $1,000, was made available to the Academy in 1949 and presented at the AAOS meeting in 1950. The Kappa Delta Awards have been presented by the Academy to persons who have performed research in orthopaedic surgery that is of high significance and impact.

The sorority increased the number of awards from one to three, and increased the dollar amount. At present three annual awards of $20,000 each are given. Two awards are named for the sorority national past presidents who were instrumental in the creation of the awards: Elizabeth Winston Lanier and Ann Doner Vaughn. The third is known as the Young Investigator Award.

The fourth award, also providing $20,000, is the OREF Clinical Research Award. Established in 1995, the award recognizes outstanding clinical research related directly to musculoskeletal disease or injury.

Torn rotator cuffs

The 2009 Young Investigator Award, given to outstanding authors who are under 40 years of age or no more than seven years beyond training, was presented to Washington University researcher Stavros Thomopoulos, Ph.D.

Dr. Thomopoulos and his research team knew that torn tendons cause a severe amount of pain and disability, and fixing them through orthopaedic surgery is no easy task. Fascinated by tissue engineering, his team took on the challenge of re-attaching tendon to bone.

"One of the challenges of my research is that connecting tendon to bone is like connecting rope to cement," stated Dr. Thomopoulos. "The mechanical properties of the two tissues are that different."

His award-winning paper, "Structure, Biomechanics, and Mechanobiology in the Attachment of Tendon to Bone"
'/>"/>

SOURCE American Academy of Orthopaedic Surgeons
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 InformEx, ... buyers and sellers of high-value chemistry, will hold the 30 ... Miami Beach Convention Center from January 21-24. ... than 3,500 attendees from top pharmaceutical, fine chemical and specialty ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Limited (the "Company") and Celtic Therapeutics Holdings LP ("Celtic ... clinical trial of SG2000 in ovarian cancer.  The trial ... of the USA, and is now actively recruiting patients ... will evaluate the overall response rate of SG2000 in ...
... (NYSE: AZN ) today announced that ... extended the time to complete its review of ... (Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO) (Logo: ... Prescription Drug User Fee Act (PDUFA) date from ...
Cached Medicine Technology:Commencement of a Phase II Clinical Trial of SG2000 in Ovarian Cancer 2Commencement of a Phase II Clinical Trial of SG2000 in Ovarian Cancer 3U.S. Food and Drug Administration Extends Review Timeline for BRILINTA (Ticagrelor) New Drug Application 2
(Date:7/9/2014)... -- Vasectomy was associated with a small increased risk ... or lethal prostate cancer according to a new study ... found that the association remained even among men who ... lethal cancer cannot be explained by diagnostic bias. It ... to look at the link between vasectomy and prostate ...
(Date:7/9/2014)... captures heretofore hidden ways that cells are regulated, scientists ... breast cancer cells more likely to metastasize. , What,s ... part by blocking two other proteins that are normally ... disease processes could have unexpected ties. , The ... Nature , points to the possibility of new ...
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective ... immunocompromised patients. This is the result of a study ... Center for Women,s Gastrointestinal Medicine at The Women,s Medicine ... online in advance of print in the American ... or C. diff , has increased to epidemic ...
(Date:7/9/2014)... By looking at ... structure and function, personality, life experiences and genetics, researchers can ... binge drinking within the next two years. Impulsivity, hopelessness, sensation-seeking ... events and a family history of drug use contribute to ... child had had a single drink at age 14 was ...
(Date:7/9/2014)... for more than watching World Cup highlights, Brian Williams ... landing in unfortunate positions on railings. A University of ... Online Journal shows that YouTube also allows researchers, ... public on topics of skin cancer and prevention. , ... the future of how we communicate around the world," ...
Breaking Medicine News(10 mins):Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:What drives a child to abuse alcohol? 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2
... Broad Institute of Harvard and MIT have received a ... ways to encourage the human body to replenish the ... by the Juvenile Diabetes Research Foundation (JDRF), the $3M ... fields, genome biology and chemical biology, to address a ...
... NASHUA, N.H., July 21 iCAD, Inc. (Nasdaq:,ICAD), ... announced the completion of its previously announced,agreement to ... medical technology company based in White Plains, NY. ... million in cash and,1,086,957 shares of iCAD common ...
... July 21 Fidelity National,Financial, Inc. (NYSE: ... insurance, claims management services and information services,today announced ... Mexico,Fidelity National Title de Mexico S.A. de C.V. ... been appointed Vice President and General,Manager and Gerardo ...
... July 21 iNutrition, Inc, (http://www.inutrition.com ) ... of Natural Nutrition, Inc, (OTC,Bulletin Board: NTNI) ... an,agreement with actor John O,Hurley ("Seinfeld," "Dancing ... endorser and spokesman for the Companies in,their ...
... melatonin strip ... BOCA RATON, Fla., July 21 TransMedia Group said it ... Sleep, all-natural,sleep aid for people who can,t wait for pills to ... asleep fast and safely. MedGen Inc.,the makers of Snorenz, which has ...
... university aligns with National League of Nursing competencies; helps address ... ... Minneapolis, MN (PRWEB) July 20, 2008 -- Capella University ... has announced a new PhD in Education specialization in Nursing ...
Cached Medicine News:Health News:Broad Institute earns grant to support pathbreaking diabetes study 2Health News:Broad Institute earns grant to support pathbreaking diabetes study 3Health News:iCAD Completes Acquisition of CAD Sciences 2Health News:Fidelity National Financial, Inc. Announces Opening of Fidelity National Title de Mexico S.A. de C.V. 2Health News:Fidelity National Financial, Inc. Announces Opening of Fidelity National Title de Mexico S.A. de C.V. 3Health News:iNutrition Signs John O'Hurley to Launch New Internet Video Campaign 2Health News:Sweet Dreams, Sweet Breath: MedGen Inc. Retains TransMedia Group to Send Media a Wake-Up Call About an All-Natural, Quick New Way to Slumber Land 2Health News:Capella University Launches Online PhD Specialization in Nursing Education 2Health News:Capella University Launches Online PhD Specialization in Nursing Education 3
... a two-level control compatible with popular ... Strips and Roche Micral test strips. ... turbidimetric immunoassays using AU Series, Bayer ... Cobas, Diasorin SPQ Test System, Dimension, ...
... the performance of Abuscreen ONLINE, AxSYM, EMIT, ... methods. This control meets current revised guidelines ... Health Services Administration (SAMSHA). Level 1 is ... analytes below screening cut-off levels (negative threshold ...
... 190 spectrophotometer is ideal for most life ... solutions, our patented* PathCheck sensor technology senses ... microplate well, and normalizes the absorbance value ... is within 5% of the value obtained ...
... This control is intended as a ... testing methods. A new feature is ... CRP. It is compatible with most ... ACS:180, Access, Dimension, Elecsys, Stratus and ...
Medicine Products: